Last updated: September 26, 2026
Gadavist, the U.S. brand name for gadobutrol, is Bayer’s macrocyclic, nonionic gadolinium-based contrast agent for magnetic resonance imaging. The product has a mature market position, broad MRI utilization, and lower clinical differentiation than newer imaging technologies. Its financial trajectory depends more on procedure volumes, hospital purchasing, supply reliability, and portfolio management than on price increases or new indications.
Bayer does not publicly disclose standalone Gadavist revenue. The product is reported within Bayer’s Radiology business, which also includes Ultravist, Primovist/Eovist, and other contrast agents. Gadavist remains commercially relevant, but its long-term growth rate is constrained by generic and private-label competition, hospital procurement pressure, and the maturity of the MRI contrast market.
What is Gadavist and how does it generate revenue?
Gadavist contains gadobutrol at a concentration of 1.0 mmol/mL. It is administered intravenously for contrast-enhanced MRI examinations. In the United States, Bayer markets Gadavist under NDA 201277. The FDA initially approved Gadavist in 2011 for use in adults and pediatric patients in specified central nervous system imaging settings, followed by supplemental approvals for additional MRI applications (FDA, 2011-2024).
The product generates revenue through several channels:
- Hospital and health-system purchases
- Outpatient imaging centers
- Academic medical centers
- Government and institutional tenders
- Distributor and group-purchasing-organization contracts
- International sales under the Gadovist brand
Gadavist is a high-concentration macrocyclic agent. Its 1.0 mmol/mL formulation allows lower injection volumes than many 0.5 mmol/mL gadolinium agents, which can support workflow and dosing efficiency in certain examinations.
How is Gadavist positioned clinically?
Gadavist competes primarily on:
- Macrocyclic molecular structure
- High gadolinium concentration
- Broad MRI labeling
- Established safety and clinical experience
- Bayer’s global radiology sales infrastructure
- Availability in prefilled and multiple-volume presentations
Macrocyclic agents are generally viewed as more kinetically stable than linear gadolinium-based agents. That distinction became commercially important after FDA and international regulators increased scrutiny of gadolinium retention. The FDA requires class labeling for gadolinium-based contrast agents, but it has not concluded that gadolinium retention identified in the brain is directly associated with adverse health effects in patients with normal renal function (FDA, 2018).
What is the FDA regulatory status of Gadavist?
Gadavist is FDA-approved as a prescription injectable contrast agent for MRI. Its U.S. regulatory history includes approvals covering:
- Central nervous system MRI
- Breast MRI
- Magnetic resonance angiography
- Pediatric use in specified age groups
- Cardiac MRI-related indications in selected settings
The exact scope of the approved label depends on the current FDA prescribing information and supplemental approvals. Gadavist is not a biologic and does not face biosimilar competition. Any follow-on product would proceed through the generic drug framework, typically under an abbreviated new drug application, if the reference-product requirements and product-specific regulatory standards are met.
What is the Orange Book status of Gadavist?
Gadavist is listed in FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations under its reference-product NDA structure. The commercial significance of the Orange Book record is narrower than for many chronic-care drugs because contrast agents are administered in institutional settings and are purchased through competitive contracts.
The key regulatory issues are:
- Whether any patents are listed against the relevant NDA
- Whether those patents have unexpired terms
- Whether a generic applicant must make a Paragraph IV certification
- Whether labeling differences create a carve-out or require a full-label product
- Whether FDA grants therapeutic-equivalence ratings to follow-on gadobutrol products
Public patent visibility for Gadavist is less straightforward than for heavily litigated small-molecule products. The core composition and formulation patents associated with gadobutrol are old relative to the 2011 U.S. approval. Any current U.S. exclusivity is therefore more likely to depend on regulatory timing, later-use patents, manufacturing know-how, or commercial execution than on a broad composition-of-matter monopoly.
What patents protect Gadavist and when does exclusivity end?
Gadavist’s patent estate has historically included patents covering gadobutrol, gadolinium complexes, pharmaceutical compositions, and contrast-agent formulations. The most commercially important early patents were filed well before U.S. approval and would normally have reached the end of their terms by the late 2010s or early 2020s, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and jurisdiction-specific rules.
Patent protection categories
| Protection category |
Relevance to Gadavist |
Current commercial effect |
| Gadobutrol chemical composition |
Protects the active contrast complex |
Core terms are mature |
| Macrocyclic gadolinium-complex chemistry |
Supports the original product platform |
Primarily historical protection |
| Injectable formulation |
May cover concentration, excipients, or stability |
Potentially relevant but narrower |
| Manufacturing process |
Can protect synthesis or purification steps |
Creates know-how barriers more than market exclusivity |
| Method-of-use patents |
May cover specific MRI applications |
Scope depends on approved labeling |
| Device or presentation patents |
May cover syringes, packaging, or delivery |
Usually limited commercial impact |
A specific active patent term should not be inferred solely from the U.S. approval date. U.S. patent term generally runs 20 years from the earliest effective nonprovisional filing date, with possible patent-term adjustment and, for eligible products, patent-term extension under 35 U.S.C. §156.
The commercial conclusion is clear: Gadavist does not appear to rely on a long-duration, unexpired composition patent comparable to the patent estates protecting recently launched specialty medicines. Generic-entry risk is therefore structurally higher than it was during the product’s launch and expansion period.
How many patents cover Gadavist?
The number of patents associated with Gadavist depends on whether the analysis includes:
- Patents specifically listed in the Orange Book
- Worldwide patent families
- Expired patents
- Continuations and divisionals
- Manufacturing patents
- Device and packaging patents
- Patents covering broader gadolinium-complex chemistry
A raw patent count would overstate practical exclusivity. The commercially relevant question is whether an unexpired U.S. patent blocks an FDA-approved generic product. Older platform patents may remain relevant to freedom-to-operate analysis but do not necessarily prevent market entry.
The strongest remaining barriers are likely to be operational:
- Validated sterile manufacturing
- High-purity gadobutrol synthesis
- Control of elemental impurities
- Consistent 1.0 mmol/mL concentration
- Stability and container-closure performance
- FDA inspection readiness
- Hospital formulary conversion costs
- Supply continuity
When does Gadavist lose exclusivity?
Gadavist’s principal U.S. small-molecule exclusivity period has effectively matured. The product’s commercial protection now depends less on classic exclusivity and more on brand preference, contracting, regulatory complexity, and Bayer’s manufacturing scale.
There is no biosimilar exclusivity issue because gadobutrol is a synthetic small molecule rather than a biologic. New indications may receive separate regulatory protection only if they meet the applicable statutory requirements and are supported by qualifying clinical evidence. Such protection would not automatically prevent approval of a generic for all non-protected indications.
Are there Paragraph IV challenges to Gadavist?
A Paragraph IV challenge is possible if a generic applicant files an ANDA and certifies that a listed patent is invalid, unenforceable, or will not be infringed. Public evidence of a major, widely reported Paragraph IV litigation campaign against Gadavist is limited.
The absence of a highly visible Paragraph IV dispute does not eliminate generic risk. It may indicate one of several conditions:
- Relevant patents have expired
- The Orange Book contains few commercially meaningful patents
- Applicants are using Paragraph III certifications
- Generic companies view the market as commercially modest
- Litigation would not materially delay approval
- Entry is being pursued through a product or labeling strategy that avoids the disputed claims
What formulations are protected by Gadavist patents?
Gadavist is supplied as a sterile aqueous solution containing gadobutrol and excipients. Formulation-related protection can involve:
- Gadobutrol concentration
- pH range
- Osmolality
- Stabilizers and buffers
- Container materials
- Prefilled syringe configuration
- Shelf-life and storage conditions
- Manufacturing and sterilization controls
Formulation patents tend to provide narrower protection than composition patents. A competing manufacturer may design around a formulation claim by changing excipients, concentration parameters, packaging, or manufacturing conditions, provided the resulting product satisfies FDA quality and bioequivalence requirements.
How does Gadavist compare with competing MRI contrast agents?
| Product |
Active ingredient |
Structure |
Primary competitive position |
| Gadavist/Gadovist |
Gadobutrol |
Macrocyclic, nonionic |
High concentration and broad global use |
| Dotarem/Clariscan |
Gadoterate meglumine |
Macrocyclic, ionic |
Strong macrocyclic safety positioning |
| ProHance |
Gadoteridol |
Macrocyclic, nonionic |
Established CNS and general MRI use |
| MultiHance |
Gadobenate dimeglumine |
Linear, ionic |
Hepatobiliary and vascular applications |
| Eovist/Primovist |
Gadoxetate disodium |
Linear, ionic |
Liver-specific imaging |
| Magnevist |
Gadopentetate dimeglumine |
Linear, ionic |
Mature, declining legacy product |
| Omniscan |
Gadodiamide |
Linear, nonionic |
Legacy product with safety-related pressure |
Gadavist’s closest commercial competitors are Dotarem and ProHance in macrocyclic MRI use. Eovist is less directly substitutable because of its hepatobiliary indication. Competition varies by hospital protocol, radiologist preference, formulary status, supply reliability, reimbursement, and contract pricing.
What is Bayer’s financial exposure to Gadavist?
Bayer does not disclose Gadavist revenue as a standalone line item. It reports radiology revenue at the portfolio level. This prevents a precise public calculation of Gadavist’s annual sales, operating margin, or product-level growth rate.
The financial trajectory can be assessed through five drivers:
MRI procedure volume
Growth in MRI utilization supports contrast demand. Aging populations, cancer surveillance, neurological diagnosis, cardiovascular imaging, and expanded outpatient imaging capacity are positive volume drivers.
Contrast utilization rate
Not every MRI examination requires contrast. Clinical guidelines, imaging protocols, renal function assessment, and the increasing use of noncontrast MRI influence the volume of gadobutrol used per scan.
Price and contracting
Hospital buyers negotiate aggressively. Contrast agents are frequently managed through portfolio contracts, distributor agreements, and group purchasing organizations. Volume-based discounts can limit net-price growth even when list prices rise.
Portfolio substitution
Bayer can protect account relationships by selling multiple contrast products. However, a hospital that converts its MRI formulary to another macrocyclic agent may reduce Gadavist utilization without changing its overall contrast budget.
Manufacturing and supply
Sterile injectable shortages can shift market share quickly. Reliable supply is a commercial advantage, particularly for large hospital systems that seek to avoid protocol disruption.
What is the generic launch risk for Gadavist?
Generic launch risk is material but may develop gradually. The market is less exposed to an immediate mass conversion than a large retail prescription market because contrast agents are institutional products and purchasing decisions are contract-driven.
Likely generic-entry scenarios
| Scenario |
Timing profile |
Commercial effect |
| No meaningful generic entry |
Near term |
Bayer retains share through contracts and reliability |
| One approved generic |
Early entry |
Selective price pressure in tenders |
| Multiple generic suppliers |
Later stage |
Faster net-price erosion and formulary substitution |
| Authorized or partner-led alternative |
Controlled entry |
Bayer may preserve part of the economics |
| Supply-constrained entry |
Any stage |
Limited substitution despite approval |
A generic competitor would need to demonstrate pharmaceutical equivalence and satisfy manufacturing requirements for a sterile injectable. The largest risks are not only patent litigation. They include product quality failures, supply interruptions, limited manufacturing capacity, and the cost of securing hospital contracts.
What litigation affects Gadavist?
Gadavist has not generated the level of publicly prominent patent litigation associated with blockbuster oncology, immunology, or diabetes drugs. The principal legal risks are likely to involve:
- ANDA patent litigation
- Orange Book listing disputes
- Patent validity challenges
- Labeling carve-outs
- Product liability claims
- Manufacturing and quality disputes
- Contracting and antitrust issues
No major settlement agreement involving a delayed generic launch is a central publicly documented feature of the Gadavist market through the available reporting period. Any settlement would need to be evaluated against its entry date, authorized-generic provisions, supply obligations, and patent scope.
What licensing deals affect Gadavist?
Gadavist is primarily a Bayer-controlled product. Its commercial history is linked to Bayer’s internal radiology portfolio and manufacturing network rather than a widely reported third-party licensing structure.
Potentially relevant commercial arrangements include:
- Regional distribution agreements
- Hospital and group-purchasing contracts
- Contract manufacturing or supply arrangements
- Product registrations held by local affiliates
- Distributor partnerships outside the United States
These arrangements can affect geographic pricing and supply but do not necessarily create additional patent exclusivity.
What geographic markets are most important for Gadavist?
Gadavist is marketed internationally as Gadovist or under related regional branding. Bayer’s geographic exposure includes North America, Europe, Asia-Pacific, and other hospital-based imaging markets.
The United States is important because of its large MRI installed base, high imaging intensity, and substantial institutional purchasing market. Europe is more exposed to centralized procurement and price regulation. Emerging markets offer procedure-volume growth but generally carry lower net prices and greater tender pressure.
How strong is the Gadavist patent estate?
The Gadavist patent estate is commercially moderate rather than strong.
| Factor |
Assessment |
| Composition-of-matter protection |
Mature |
| Regulatory exclusivity |
Largely exhausted for the original product |
| Formulation protection |
Potentially narrow |
| Method-of-use protection |
Indication-dependent |
| Manufacturing know-how |
Meaningful operational barrier |
| Brand and clinical adoption |
Stronger than current patent exclusivity |
| Generic litigation barrier |
Limited to any active, enforceable claims |
| Biosimilar risk |
Not applicable |
Bayer’s durable advantages are brand recognition, clinical familiarity, supply capability, global registrations, and portfolio contracting. Those advantages can delay share loss but generally do not prevent generic entry.
Key Takeaways
- Gadavist is Bayer’s gadobutrol-based macrocyclic MRI contrast agent.
- Bayer does not disclose standalone Gadavist revenue, so product-level financial estimates are not publicly verifiable.
- The drug is commercially mature, with growth tied to MRI procedure volumes and hospital contracts.
- Its original composition and platform patent protection is largely historical.
- Formulation, manufacturing, packaging, and method-of-use patents may remain relevant but are narrower.
- Gadavist has no biosimilar exposure because it is a synthetic small molecule.
- Generic risk is material, although institutional procurement may produce gradual rather than immediate substitution.
- Bayer’s main defenses are supply reliability, portfolio breadth, clinical familiarity, and contracting scale.
- Dotarem and ProHance are the closest macrocyclic competitors; Eovist competes in a more specialized liver-imaging segment.
- The most important financial risk is net-price erosion after credible generic or private-label supply becomes available.
FAQs About Gadavist Market and Patent Risk
Is Gadavist a biologic or a small-molecule drug?
Gadavist is a synthetic small-molecule gadolinium-based contrast agent. It is not a biologic and is not subject to the U.S. biosimilar pathway.
Does Gadavist have a patent-protected chemical structure?
The underlying gadobutrol and related gadolinium-complex technology were protected by earlier patent families, but the core protection is mature relative to the product’s U.S. launch. Current commercial barriers are more likely to involve narrower claims and manufacturing capabilities.
What drug is most similar to Gadavist?
Dotarem and ProHance are the closest clinical and commercial comparators because both are macrocyclic gadolinium-based MRI contrast agents. Their formulation, concentration, labeling, and procurement positions differ.
Can a generic gadobutrol replace Gadavist automatically?
No. FDA approval and therapeutic-equivalence status are required, and hospitals must still evaluate formulary policy, supply reliability, packaging, workflow, and contracting terms.
Why does Bayer not report Gadavist sales separately?
Bayer reports revenue by business and product portfolio rather than disclosing every individual radiology product. Gadavist sales are included within the company’s broader Radiology reporting.
References
-
Bayer AG. (2024). Annual report 2023. Bayer AG.
-
Bayer AG. (2024). Quarterly and annual financial reporting: Pharmaceuticals and radiology. Bayer AG.
-
U.S. Food and Drug Administration. (2011). FDA approves Gadavist injection for use in central nervous system MRI. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2018). FDA identifies no adverse health effects with brain retention of gadolinium-based contrast agents for MRI. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Gadavist: Prescribing information. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
-
U.S. Patent and Trademark Office. (2024). Patent term adjustment and patent term extension resources. U.S. Department of Commerce.
